16 marzo 2015
Of prostate cancer patients with combination MAP3K7 and CHD1 deletions, about 50 percent will have recurrent prostate cancer, which ultimately leads to death, a study concludes. About 10 percent of all prostate cancers harbor combined MAP3K7-CHD1 deletions.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/CEfCzWc1k0Y/150316121248.htm
